Literature DB >> 29936459

Laminarin Promotes Immune Responses and Normalizes Glutamic Oxaloacetic Transaminase and Glutamic Pyruvic Transaminase Levels in Leukemic Mice In Vivo.

Hung-Sheng Shang1,2, Yung-Luen Shih3,4,5, Chao-Ping Chen1, Mei-Hui Lee6, Hsu-Feng Lu7,8, Pei-Yi Chou8, Nien-Chieh Liao8, Yung-Liang Chen9, Shu-Ching Hsueh10,11, Jing-Gung Chung12,13.   

Abstract

BACKGROUND/AIM: Laminarin, mainly found in the fronds of Laminaria, has antimicrobial characteristics and induces immune responses. However, there are no available information to show the laminarin effect on glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) levels in mice with leukemia in vivo.
MATERIALS AND METHODS: Fifty normal BALB/c mice were separated randomly into five groups. Group I mice received normal diet as control. Leukemia was generated in groups II-V using WEHI-3 cells: Group II mice received normal diet as positive control; group III, IV and V mice received laminarin at 1, 2.5 and 5 mg/ml with ddH2O, respectively, by oral gavage every 2 days for 14 days (total of seven times). All mice were weighed during the treatment. After treatment, mice were sacrificed, blood was collected for determination of cell markers, liver and spleen samples were weighed, and spleens were used for phagocytosis and natural killer (NK) cell activity and cell proliferation using flow cytometric assay.
RESULTS: Laminarin did not affect animal appearances, but increased the body weight at all doses. It reduced the weight of liver at 2.5 and 5 mg/ml and of spleen at 5 mg/ml. Laminarin increased CD3 (2.5 mg/ml) and CD19 (1 and 5 mg/ml) cell populations but reduced CD11b (5 mg/ml) cell populations, however, these did not affect Mac-3 marker level. Laminarin at 1 mg/ml increased phagocytosis by macrophages from peripheral blood mononuclear cell, but did not affect those from the peritoneal cavity. Laminarin increased NK cell cytotoxic activity at all doses and at a target ratio of 25:1 and 50:1. Laminarin did not affect B-cell proliferation, but at 5 mg/ml significantly reduced T-cell proliferation. Laminarin restored glutamate oxaloacetate transaminase (2.5 and 5 mg/ml) and glutamate pyruvate transaminase (2.5 mg/ml) levels. Based on these results, we suggest that laminarin can promote immune responses and protect against liver injury. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Laminarin; glutamic oxaloacetic transaminase; glutamic pyruvic transaminase; immune response; leukemia BALB/c mice

Mesh:

Substances:

Year:  2018        PMID: 29936459      PMCID: PMC6117764          DOI: 10.21873/invivo.11308

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  30 in total

1.  Determination of leukocyte elastase concentration in plasma and serum by a simple method using a specific synthetic substrate.

Authors:  Y Nagamatsu; J Yamamoto; A Fukuda; M Ohta; Y Tsuda; Y Okada
Journal:  Haemostasis       Date:  1991

2.  Human intestinal epithelial cells respond to β-glucans via Dectin-1 and Syk.

Authors:  Sarit Cohen-Kedar; Liran Baram; Hofit Elad; Eli Brazowski; Hanan Guzner-Gur; Iris Dotan
Journal:  Eur J Immunol       Date:  2014-10-27       Impact factor: 5.532

3.  Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides.

Authors:  H Q Miao; M Elkin; E Aingorn; R Ishai-Michaeli; C A Stein; I Vlodavsky
Journal:  Int J Cancer       Date:  1999-10-29       Impact factor: 7.396

4.  An initial event in the insect innate immune response: structural and biological studies of interactions between β-1,3-glucan and the N-terminal domain of β-1,3-glucan recognition protein.

Authors:  Huaien Dai; Yasuaki Hiromasa; Daisuke Takahashi; David VanderVelde; Jeffrey A Fabrick; Michael R Kanost; Ramaswamy Krishnamoorthi
Journal:  Biochemistry       Date:  2012-12-20       Impact factor: 3.162

Review 5.  Current treatment of acute myeloid leukemia.

Authors:  Gail J Roboz
Journal:  Curr Opin Oncol       Date:  2012-11       Impact factor: 3.645

Review 6.  Why Is Progress in Acute Myeloid Leukemia So Slow?

Authors:  Elihu Estey
Journal:  Semin Hematol       Date:  2015-03-17       Impact factor: 3.851

Review 7.  Redox control of inflammation in macrophages.

Authors:  Bernhard Brüne; Nathalie Dehne; Nina Grossmann; Michaela Jung; Dmitry Namgaladze; Tobias Schmid; Andreas von Knethen; Andreas Weigert
Journal:  Antioxid Redox Signal       Date:  2013-03-06       Impact factor: 8.401

8.  Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.

Authors:  K Kondo; H Shaim; P A Thompson; J A Burger; M Keating; Z Estrov; D Harris; E Kim; A Ferrajoli; M Daher; R Basar; M Muftuoglu; N Imahashi; A Alsuliman; C Sobieski; E Gokdemir; W Wierda; N Jain; E Liu; E J Shpall; K Rezvani
Journal:  Leukemia       Date:  2017-10-03       Impact factor: 11.528

Review 9.  Innate and adaptive T cells in influenza disease.

Authors:  Simone Nüssing; Sneha Sant; Marios Koutsakos; Kanta Subbarao; Thi H O Nguyen; Katherine Kedzierska
Journal:  Front Med       Date:  2018-01-20       Impact factor: 9.927

10.  A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression.

Authors:  Heather E Stefanski; Leslie Jonart; Emily Goren; James J Mulé; Bruce R Blazar
Journal:  PLoS One       Date:  2018-04-04       Impact factor: 3.240

View more
  1 in total

1.  Pre-Treatment with Laminarin Protects Hippocampal CA1 Pyramidal Neurons and Attenuates Reactive Gliosis Following Transient Forebrain Ischemia in Gerbils.

Authors:  Tae-Kyeong Lee; Ji Hyeon Ahn; Cheol Woo Park; Bora Kim; Young Eun Park; Jae-Chul Lee; Joon Ha Park; Go Eun Yang; Myoung Cheol Shin; Jun Hwi Cho; Il-Jun Kang; Moo-Ho Won
Journal:  Mar Drugs       Date:  2020-01-12       Impact factor: 5.118

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.